Brivaracetam is under clinical development by UCB and currently in Phase III for Epilepsy. According to GlobalData, Phase III drugs for Epilepsy have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Brivaracetam’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Brivaracetam overview

Brivaracetam (Briviact / Brivlera) the 4-n-propyl analog of levetiracetam, is a racetam derivative acts as an anticonvulsant agent. It is formulated as film-coated tablets, solution for oral route of administration and solution for intravenous route of administration. Briviact is indicated as an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization (spreading to both sides of the brain after the initial seizure) in adult and adolescent patients from 16 years of age with epilepsy. Briviact is indicated as an add-on treatment to other medications to treat partial onset seizures in patients age 16 years and older with epilepsy. Brivlera (brivaracetam) is indicated as adjunctive therapy in the management of partial-onset seizures in patients 4 years of age and older with epilepsy who are not satisfactorily controlled with conventional therapy. Briviact is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.

Brivaracetam is under development for the treatment of childhood absence epilepsy (childhood epilepsy) and juvenile absence epilepsy (Epilepsy). It was also under development for postherpetic neuralgia and unverricht lundborg disease (ULD), symptomatic myoclonus and partial seizure.

Brivaracetam was under development for the treatment of neonatal seizures.

UCB overview

UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.

For a complete picture of Brivaracetam’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.